Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Experimental & Molecular Medicine
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. experimental & molecular medicine
  3. articles
  4. article
Trichostatin A-mediated upregulation of p21WAF1 contributes to osteoclast apoptosis
Download PDF
Download PDF
  • Article
  • Open access
  • Published: 01 April 2007

Trichostatin A-mediated upregulation of p21WAF1 contributes to osteoclast apoptosis

  • TacGhee Yi1,
  • Jeong-Hwa Baek,
  • Hye-Jin Kim,
  • Mi-Hye Choi,
  • Sang-Beom Seo,
  • Hyun-Mo Ryoo,
  • Gwan-Shik Kim &
  • …
  • Kyung Mi Woo 

Experimental & Molecular Medicine volume 39, pages 213–221 (2007)Cite this article

  • 921 Accesses

  • 39 Citations

  • Metrics details

Abstract

Histone deacetylase inhibitors (HDIs), a new class of anti-cancer agents, have been reported to suppress formation of osteoclast precursors and their fusion into multinucleated cells. However, little is known about the effect of HDIs on mature osteoclasts, which may have significance for their therapeutic use. Here, we demonstrate a novel action of HDIs on osteoclast apoptosis. Primary multinucleated mature osteoclasts were prepared from mouse bone marrow cells. Treatment of osteoclasts with the HDI trichostatin A (TSA) caused apoptosis, as confirmed by annexin V staining and caspase activation. TSA caused the upregulation of p21WAF1 in osteoclasts. To understand the role of p21WAF1 upregulation in TSA-treated osteoclasts, shRNA against p21WAF1-containing lentivirus was introduced into osteoclasts. The suppression of p21WAF1 decreased TSA-directed osteoclast apoptosis. Collectively, our results provide evidence that TSA causes osteoclast apoptosis, which involves, in part, TSA-induced upregulation of p21WAF1, and strongly supports HDIs as potential therapeutic agents for excessive bone resorption.

Similar content being viewed by others

Clustered peptide regulating the multivalent interaction between RANK and TRAF6 inhibits osteoclastogenesis by fine-tuning signals

Article Open access 22 April 2025

TAZ inhibits osteoclastogenesis by attenuating TAK1/NF-κB signaling

Article Open access 12 July 2021

Hypoxia-inducible factor-2α mediates senescence-associated intrinsic mechanisms of age-related bone loss

Article Open access 02 April 2021

Article PDF

Author information

Authors and Affiliations

  1. Department of Cell and Developmental Biology, Dental Research Institute and BK21 Program School of Dentistry, Seoul National University, Seoul, 110-749, Korea

    TacGhee Yi

Authors
  1. TacGhee Yi
    View author publications

    Search author on:PubMed Google Scholar

  2. Jeong-Hwa Baek
    View author publications

    Search author on:PubMed Google Scholar

  3. Hye-Jin Kim
    View author publications

    Search author on:PubMed Google Scholar

  4. Mi-Hye Choi
    View author publications

    Search author on:PubMed Google Scholar

  5. Sang-Beom Seo
    View author publications

    Search author on:PubMed Google Scholar

  6. Hyun-Mo Ryoo
    View author publications

    Search author on:PubMed Google Scholar

  7. Gwan-Shik Kim
    View author publications

    Search author on:PubMed Google Scholar

  8. Kyung Mi Woo
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Yi, T., Baek, JH., Kim, HJ. et al. Trichostatin A-mediated upregulation of p21WAF1 contributes to osteoclast apoptosis. Exp Mol Med 39, 213–221 (2007). https://doi.org/10.1038/emm.2007.24

Download citation

  • Published: 01 April 2007

  • Issue date: 01 April 2007

  • DOI: https://doi.org/10.1038/emm.2007.24

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • apoptosis
  • CDKN1A protein, mouse
  • cyclin-dependent kinase inhibitor p21
  • histone deacetylases
  • osteoclasts
  • RNA interference
  • trichostatin A

This article is cited by

  • Harnessing the HDAC–histone deacetylase enzymes, inhibitors and how these can be utilised in tissue engineering

    • Liam Lawlor
    • Xuebin B. Yang

    International Journal of Oral Science (2019)

  • BMSCs reduce rat granulosa cell apoptosis induced by cisplatin and perimenopause

    • Jun-qi Guo
    • Xia Gao
    • Jian-ming Tan

    BMC Cell Biology (2013)

  • Analysis of histone deacetylase inhibitor-induced responses in human periodontal ligament fibroblasts

    • Tae-Il Kim
    • Ji-Eun Han
    • Kyung Mi Woo

    Biotechnology Letters (2013)

  • REG gamma: a potential marker in breast cancer and effect on cell cycle and proliferation of breast cancer cell

    • Xiaoyi Wang
    • Shengfen Tu
    • Guosheng Ren

    Medical Oncology (2011)

  • The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models

    • S Deleu
    • M Lemaire
    • K Vanderkerken

    Leukemia (2009)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Special Feature
  • Journal Information
  • About the Editors
  • About the Partner
  • Contact
  • For Advertisers
  • Press Releases
  • Open Access Fees and Funding

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Experimental & Molecular Medicine (Exp Mol Med)

ISSN 2092-6413 (online)

ISSN 1226-3613 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited